Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRST
2016-003592-21Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of secukinumab in plaque psoriasis (2 arms), sponsored by Novartis. Primary endpoint: Area under the curve for PASI percentage change from baseline over 32 weeks. Started Oct 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2016-003592-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003592-21.